ערך בספרים למניה: delcath.com (DCTH)

Delcath Systems, Inc. (DCTH) provides unique liver chemotherapy equipment, ensuring stable demand for high-cost components through implementation in medical centers. The asset's market value dynamics on GURU.Markets currently stand at 3.51. While geopolitical tensions and sanctions complicate global logistics and the conduct of research, the approval of the HEPZATO KIT transitions the company to a stage of active commercial scaling for metastasis therapy.

Finding a balance between operational risks and return on capital requires an analysis of net assets, which for Delcath Systems, Inc. (DCTH) with its asset-light model and outsourced production, are primarily concentrated in intellectual property. The trend in book value per common share reflects the company's residual capital after deducting liabilities, allowing investors to assess the intrinsic value of the business and the level of investment protection against market revaluation.